

# Maria Mercedes Santoro

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5376425/maria-mercedes-santoro-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114  
papers

1,596  
citations

21  
h-index

34  
g-index

122  
ext. papers

1,939  
ext. citations

5.3  
avg, IF

3.96  
L-index

#	Paper	IF	Citations
114	Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1374	4.9	0
113	Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.. <i>Microbiology Spectrum</i> , <b>2022</b> , e0273221	8.9	6
112	Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches.. <i>Infection, Genetics and Evolution</i> , <b>2022</b> , 101, 105294	4.5	0
111	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 59, 106492	14.3	1
110	High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2021</b> , 102, 115574	2.9	0
109	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1038.e1-1038.e6	9.5	
108	Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon. <i>HIV Medicine</i> , <b>2021</b> , 22, 567-580	2.7	0
107	The impact of DAA-mediated HCV eradication on CD4 and CD8 T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 779-786	3.4	2
106	The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. <i>Reviews in Medical Virology</i> , <b>2021</b> , e2261	11.7	6
105	HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253587	3.7	1
104	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 57, 106252	14.3	5
103	Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , <b>2021</b> , 22, 519-525	2.7	1
102	Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1277-1285	5.1	2
101	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 3272-3279	5.1	
100	Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon. <i>AIDS Research and Therapy</i> , <b>2020</b> , 17, 14	3	1
99	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106027	14.3	5
98	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2547-2553	5.1	8

97	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1778-1786	5.1	6
96	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, e24-e28	3.1	1
95	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1026-1030	5.1	12
94	HIV MDR is still a relevant issue despite its dramatic drop over the years. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1301-1310	5.1	8
93	HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , <b>2020</b> , 9, 93	3	0
92	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , <b>2020</b> , 53, 100721	23.2	44
91	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa456	1	5
90	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , <b>2020</b> , 130, 104534	14.5	3
89	Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235958	3.7	2
88	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5
87	First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. <i>Antimicrobial Resistance and Infection Control</i> , <b>2020</b> , 9, 143	6.2	4
86	Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 20, 163-169	3.4	5
85	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , <b>2019</b> , 19, 1291	4.1	3
84	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25227	5.4	24
83	Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. <i>Journal of Clinical Virology</i> , <b>2019</b> , 117, 61-67	14.5	13
82	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , <b>2019</b> , 95, 619-625	2.8	9
81	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 321-331	1.6	3
80	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , <b>2019</b> , 116, 23-28	14.5	3

79	HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 246	4	6
78	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , <b>2019</b> , 55, 290-297	2.3	
77	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , <b>2019</b> , 93, 50-59	2.9	2
76	Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study). <i>BMC Pediatrics</i> , <b>2019</b> , 19, 226	2.6	3
75	Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat". <i>AIDS Research and Therapy</i> , <b>2019</b> , 16, 36	3	10
74	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 614-617	5.1	16
73	Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. <i>New Microbiologica</i> , <b>2019</b> , 42, 69-80	1.1	
72	Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. <i>Medicine (United States)</i> , <b>2018</b> , 97, e0176	1.8	12
71	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , <b>2018</b> , 104, 61-64	14.5	11
70	Viro-immunological response of drug-naïve HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 249-257	1.6	6
69	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , <b>2018</b> , 8, 15739	4.9	0
68	Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 2480-2484	5.1	11
67	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ cp/mL. <i>Infection</i> , <b>2017</b> , 45, 521-528	5.8	9
66	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , <b>2017</b> , 18, 225-235	8.8	25
65	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , <b>2017</b> , 23, 267.e1-267.e4	9.5	7
64	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2837-2845	5.1	13
63	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 2827-2837	9.7	9
62	Brief Report: Drop in CD4+ Counts Below 200 Cells/ $\mu$ l After Reaching (or Starting From) Values Higher than 350 Cells/ $\mu$ l in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 417-422	3.1	1

61	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 465-471	3.1	3
60	Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. <i>HIV Medicine</i> , <b>2017</b> , 18, 21-32	2.7	7
59	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. <i>Current HIV Research</i> , <b>2017</b> , 15, 66-73	1.3	3
58	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , <b>2017</b> , 19,	1.5	3
57	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 855-865	5.1	7
56	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 739-50	5.1	12
55	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 565-575	25.5	175
54	Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. <i>Aids</i> , <b>2016</b> , 30, 731-41	3.5	8
53	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1352-60	5.1	3
52	Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. <i>AIDS Research and Human Retroviruses</i> , <b>2016</b> , 32, 329-33	1.6	4
51	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156360	3.7	
50	High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. <i>Current HIV Research</i> , <b>2016</b> , 14, 165-71	1.3	20
49	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 71, 263-71	3.1	33
48	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , <b>2016</b> , 7, 1-7	3.4	2
47	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , <b>2016</b> , 82, 94-100	14.5	22
46	HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. <i>Current HIV Research</i> , <b>2016</b> ,	1.3	1
45	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , <b>2015</b> , 16, 297-306	2.7	8
44	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 2935-41	9.7	4

43	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1865-73	5.1	19
42	Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. <i>Journal of Infection</i> , <b>2015</b> , 70, 288-98	18.9	9
41	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140877	3.7	7
40	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135325	3.7	14
39	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , <b>2015</b> , 38, 443-90	1.1	6
38	The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: evidences from literature. <i>Journal of Infection</i> , <b>2014</b> , 69, 408-10	18.9	2
37	Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy. <i>Aids</i> , <b>2014</b> , 28, 2531-9	3.5	25
36	Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1156-64	11.6	55
35	A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. <i>PLoS ONE</i> , <b>2014</b> , 9, e105853	3.7	9
34	Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. <i>HIV Medicine</i> , <b>2013</b> , 14, 571-7	2.7	7
33	HIV-1 Genetic Variability and Clinical Implications. <i>ISRN Microbiology</i> , <b>2013</b> , 2013, 481314		81
32	Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study. <i>BioMed Research International</i> , <b>2013</b> , 2013, 810617	3	8
31	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2205-9	5.1	8
30	Impact of pre-therapy viral load on virological response to modern first-line HAART. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 867-76	1.6	31
29	The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. <i>PLoS ONE</i> , <b>2013</b> , 8, e53603	3.7	14
28	The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. <i>Clinical Microbiology and Infection</i> , <b>2012</b> , 18, E289-98	9.5	16
27	Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. <i>Journal of Medical Virology</i> , <b>2012</b> , 84, 721-7	19.7	29
26	Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 1285-93	1.6	16

25	HIV-1 non-B subtypes in Italy: a growing trend. <i>New Microbiologica</i> , <b>2012</b> , 35, 377-86	1.1	18
24	Genetic diversity of HIV type 1 in Montenegro. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 921-4	1.6	14
23	Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 489-97	1.6	10
22	Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. <i>Pediatric Infectious Disease Journal</i> , <b>2011</b> , 30, 1062-8	3.4	36
21	Sentinel mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2615-23	5.1	13
20	Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. <i>Archives of Virology</i> , <b>2011</b> , 156, 1235-43	2.6	29
19	Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. <i>ChemMedChem</i> , <b>2011</b> , 6, 2203-13	3.7	12
18	Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 1173-82	1.6	20
17	Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 336-44	2.1	29
16	Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2010</b> , 42, 237-9		1
15	Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 156-60	3.1	42
14	Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 53, 150-1	3.1	
13	Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 1011-9	1.6	14
12	Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. <i>Infection</i> , <b>2009</b> , 37, 233-43	5.8	8
11	Dynamics of NRTI resistance mutations during therapy interruption. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 57-64	1.6	11
10	Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 157-64	1.6	18
9	Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 1133-8	1.6	15
8	The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 771-9	1.6	31

7	Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 1408-18	7-18	34
6	Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study. <i>AIDS Patient Care and STDs</i> , <b>2008</b> , 22, 7-16	5.8	18
5	Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. <i>Journal of Virology</i> , <b>2007</b> , 81, 11507-19	6.6	55
4	Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. <i>Journal of Virology</i> , <b>2006</b> , 80, 7186-98	6.6	63
3	Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. <i>New Microbiologica</i> , <b>2006</b> , 29, 89-100	1.1	3
2	Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 2015-25	5.9	51
1	High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. <i>Journal of Virology</i> , <b>2005</b> , 79, 10718-29	6.6	50